NEW HAVEN: Melinta Therapeutics, Inc. [Nasdaq:MLNT], a commercial-stage company, developing commercializing novel antibiotics to treat serious bacterial infections, has appointed Peter Milligan as its new Chief Financial Officer, effective immediately. He will succeed current CFO Paul Estrem, who is retiring from Melinta on October 1.
A Melinta release says “Milligan is an accomplished executive and established corporate leader who brings nearly 30 years of financial leadership experience, with extensive experience in managing all aspects of corporate and operational financial matters, including numerous capital market transactions.”
“We are excited to have Peter join our leadership team at this important moment for Melinta,” said Dan Wechsler, President and CEO of Melinta. “His nearly three decades of financial leadership experience across all aspects of corporate and operational finance will be a strong asset to our company as we continue to grow and build upon our position as the world’s leading dedicated antibiotics company.”
Milligan most recently served as the Chief Financial Officer of G&W Laboratories, a privately held generic pharmaceutical company. Prior to that he was Senior Vice President and CFO of Exelis, Inc. (NYSE:XLS), a leading global defense and aerospace company
Milligan holds a M.B.A. from New York University with a concentration in Finance and Economics and a B.B.A. in Accounting from Hofstra University.